← Leaderboards
John Gledhill
Evogen, Inc.
$841,634
Attributed
$841,634
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $786.6K · FY2019–20$1M$750K$500K$250K$0
'19
'20
Funding mix
By agency
NIH$841,634 · 2
By mechanism
R43$841,634 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Diagnostic”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$293,634,608
- Lynn Briscoe · Leidos Biomedical Research, Inc.$100,239,656
- Leonard Freedmand · Leidos Biomedical Research, Inc.$63,918,621
- Mark Marino · Venturewell$61,502,138
- Scott Topper · Broad Institute, Inc.$51,811,587
Research focus
DiagnosticHealthcare SystemsPlasma ProteinsSeizuresNeurologicEventMedicalPhysiciansSamplingEpilepsyDiagnosisClia CertifiedCostAntiepileptic AgentsBrainEnzyme-Linked Immunosorbent AssayBlood TestsClinical ResearchAlgorithmsEnrollmentClinical CareBloodAccurate DiagnosisDiagnostic Tests
Grant awards (3)
Assessment of Peripherally Circulating Plasma Proteins and Clinical Risks toDifferentiate Epileptic Seizure from Psychogenic Nonepileptic Seizure$55,000
R43 · FY2020 · NS · contact PI
Assessment of Peripherally Circulating Plasma Proteins and Clinical Risks to Differentiate Epileptic Seizure from Psychogenic Nonepileptic Seizure$562,119
R43 · FY2019 · NS · contact PI
Diagnostic Test for Detecting Recent Seizures in Epilepsy Patients$224,515
R43 · FY2019 · NS · contact PI